Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors

The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be overexpressed on the surface of a wide variety of tumor cells. Therefore, the peptides B6 (TfR specific) and GE11 (targeted to the EGFR) were linked to the PAMAM (polyamidoamine) structure via a polyethylenglycol (PEG) 2 kDa chain with the aim of improving the silencing capacity of the PAMAM-based dendriplexes. The complexes showed an excellent binding capacity to the siRNA with a maximal condensation at nitrogen/phosphate (N/P) 2. The nanoparticles formed exhibited hydrodynamic diameters below 200 nm. The zeta potential was always positive, despite the complexes containing the PEG chain in the structure showing a drop of the values due to the shielding effect. The gene silencing capacity was assayed in HeLa and LS174T cells stably transfected with the eGFPLuc cassette. The dendriplexes containing a specific anti luciferase siRNA, assayed at different N/P ratios, were able to mediate a mean decrease of the luciferase expression values of 14% for HeLa and 20% in LS174T cells, compared to an unspecific siRNA-control. (p < 0.05). In all the conditions assayed, dendriplexes resulted to be non-toxic and viability was always above 75%.

[1]  M. Ogris,et al.  Systemic tumor‐targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes , 2017, The journal of gene medicine.

[2]  Min Liu,et al.  Peptide GE11–Polyethylene Glycol–Polyethylenimine for targeted gene delivery in laryngeal cancer , 2015, Medical Oncology.

[3]  Tom C. Karagiannis,et al.  Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy , 2014, The Journal of Membrane Biology.

[4]  Jiangyu Wu,et al.  Dendrimers as Carriers for siRNA Delivery and Gene Silencing: A Review , 2013, TheScientificWorldJournal.

[5]  Chen Jiang,et al.  T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.

[6]  Quanyin Hu,et al.  B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. , 2013, Bioconjugate chemistry.

[7]  M. Ogris,et al.  Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Ogris,et al.  Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. , 2013, Molecular pharmaceutics.

[9]  Jianqing Gao,et al.  Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. Schwaiger,et al.  Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus , 2012, Gene Therapy.

[11]  T. Niidome,et al.  Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. , 2012, Molecular pharmaceutics.

[12]  Ernst Wagner,et al.  Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[14]  T. Higashi,et al.  Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for DNA, shRNA and siRNA , 2012, Pharmaceutics.

[15]  Ling Peng,et al.  Dendrimers as non-viral vectors for siRNA delivery , 2012 .

[16]  Sabrina Pricl,et al.  Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. , 2012, Molecular pharmaceutics.

[17]  T. Higashi,et al.  Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  H. M. Nielsen,et al.  Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: effect of dendrimer charge density. , 2011, International journal of pharmaceutics.

[19]  D. Schaffert,et al.  Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. , 2011, Human gene therapy.

[20]  M. Grinstaff,et al.  Biomedical applications of dendrimers: a tutorial. , 2011, Chemical Society reviews.

[21]  R. Senekowitsch-Schmidtke,et al.  Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. , 2011, Human gene therapy.

[22]  S. Hart,et al.  Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[23]  D. Schaffert,et al.  Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier , 2011, Pharmaceutical Research.

[24]  W. A. Yeudall,et al.  Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. , 2010, Oral oncology.

[25]  J. Marks,et al.  Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. , 2010, Cancer research.

[26]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[27]  M. Morilla,et al.  Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. , 2009, International journal of pharmaceutics.

[28]  J. Irudayaraj,et al.  Receptor overexpression or inhibition alters cell surface dynamics of EGF-EGFR interaction: new insights from real-time single molecule analysis. , 2009, Biochemical and biophysical research communications.

[29]  M. Brechbiel,et al.  Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. , 2008, Cancer biotherapy & radiopharmaceuticals.

[30]  M. Watson,et al.  Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines , 2008, Journal of Nuclear Medicine.

[31]  F. Hirayama,et al.  Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. , 2008, Journal of pharmaceutical sciences.

[32]  K. Kono,et al.  Effect of transferrin as a ligand of pH-sensitive fusogenic liposome-lipoplex hybrid complexes. , 2008, Bioconjugate chemistry.

[33]  Cheng-Cai Zhang,et al.  Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. , 2007, Organic & biomolecular chemistry.

[34]  Hidetoshi Arima,et al.  Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[35]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[36]  Ernst Wagner,et al.  The internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Ling Peng,et al.  PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. , 2006, Chemical communications.

[38]  Ming Yao,et al.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Haibin Xia,et al.  Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium , 2000, Journal of Virology.

[40]  D. Lauffenburger,et al.  Targeted synthetic gene delivery vectors. , 2000, Current opinion in molecular therapeutics.

[41]  W. Eckelman,et al.  Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  F. Szoka,et al.  In vitro gene delivery by degraded polyamidoamine dendrimers. , 1996, Bioconjugate chemistry.

[43]  C. Bräuchle,et al.  Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[44]  V. Torchilin,et al.  Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. , 2013, Biomaterials.

[45]  E. Giralt,et al.  Solid-phase-assisted synthesis of targeting peptide – PEG – oligo ( ethane amino ) amides for receptor-mediated gene delivery † , 2012 .

[46]  J. Park,et al.  Effect of Poly(ethylene glycol)Grafting on Polyethylenimine as a Gene Transfer Vector in vitro , 2001 .